Conquer Cancer Foundation <http://conquercancerfoundation.org/> •
Cancer.Net <http://www.cancer.net> • Journal of Clinical Oncology
</portal/jsp/ASCOV2/singlesignon/ascopubs_login.jsp?ascopubs_url=http://jco.ascopubs.org/>
• Journal of Oncology Practice
</portal/jsp/ASCOV2/singlesignon/ascopubs_login.jsp?ascopubs_url=http://jop.ascopubs.org/>


ASCO University <http://university.asco.org/> • Quality Oncology
Practice Initiative (QOPI) <http://qopi.asco.org/> • ASCO Connection
<http://connection.asco.org/>
ASCO: American Society of Clinical Oncology </portal/site/ascov2>

View Sitemap </ASCOv2/About+ASCO/Sitemap>
A-Z Indexed Sitemap </ASCOv2/About+ASCO/Sitemap+A2Z>
Advanced Search </ASCOv2/Advanced+Search>
ASCO SIGN IN 	Manage Email Subscriptions
</ASCOv2/MyASCO/Update+Email+Subscriptions>

Username: 		
Create an account
<https://store.asco.org/public/eCommerce/Security/ASCORegistration.aspx?confirmMessage=true&dest_url=2f4153434f76322f4d656574696e67732f4162737472616374733f766d766965773d616273745f64657461696c5f7669657726636f6e6649443d31313626616273747261637449443d3839363332>

Why Be A Member? <http://benefits.asco.org/>

Password: 		
[question] 		Remember me 	Forgot your username
</portal/site/ascov2/template.CREDENTIALS_MGMT> or password
</portal/site/ascov2/template.CREDENTIALS_MGMT>?

ASCO Membership Directory
</ASCOv2/MyASCO/Membership+Directory?intcmp=membdir-signin>

The Remember Me feature is an automatic login process which creates a
cookie on the hard drive of your computer containing a unique identifier
which ASCO.org will utilize to remember you by, thereby avoiding the
need to enter username and password upon subsequent visits to ASCO.org.
DO NOT select this option if you share this computer with others since
transactional, personal, or member only information will be accessible
by other users.

To activate the Remember Me option, click the empty check box when
signing in to the site. The Remember Me functionality is deactivated at
the logout.

For additional information please review our Privacy Policy
</ASCOv2/About+ASCO/Privacy+Policy>.

  Home   </portal/site/ascov2>	
	    About ASCO   </ASCOv2/About+ASCO>

	
	    MyASCO   </ASCOv2/MyASCO>

	
	    Cancer Portals   </ASCOv2/Cancer+Portals>

	
	    Products   </ASCOv2/Products>

	
	    Meetings   </ASCOv2/Meetings>

	
	    Donate   </ASCOv2/Donate>

	
	    Join ASCO   </ASCOv2/Join+ASCO>

<#>

  * Practice & Guidelines </ASCOv2/Practice+%26+Guidelines>
  * Research Resources </ASCOv2/Research+Resources>
  * Education & Training </ASCOv2/Education+%26+Training>
  * Public Policy </ASCOv2/Public+Policy>
  * International Affairs </ASCOv2/International+Affairs>
  * Grants & Awards </ASCOv2/Grants+%26+Awards>
  * MultiMedia </ASCOv2/MultiMedia>
  * Press Center </ASCOv2/Press+Center>

	
ASCO Home </ASCOv2>   arrow   Meetings </ASCOv2/Meetings>   arrow  
Abstracts </ASCOv2/Meetings/Abstracts>     arrow   2012 Genitourinary
Cancers Symposium
</ASCOv2/Meetings/Abstracts?&vmview=abst_meeting_categories_view&confID=116>
 
Bookmark and Share <http://www.addthis.com/bookmark.php?v=20>


    Treatment of metastatic renal cancer with high-dose interleukin-2
    after targeted therapy.

	Print
</portal/site/ASCOv2/template.RAW/menuitem.a1c60e38cd6d5b9f01ae0094ef37a01d/;jsessionid=nrPGP0DZ9wpJZGwwD0X42pHy9YK8vJrmRblB15kXTv7GMrvnyzDj!-36294903!252569393?javax.portlet.tpst=b2e033002b246c2828a46427ef37a01d_ws_RW&javax.portlet.prp_b2e033002b246c2828a46427ef37a01d_viewID=abst_detail_rawview&javax.portlet.begCacheTok=com.vignette.cachetoken&javax.portlet.endCacheTok=com.vignette.cachetoken&index=n&confID=116&abstractID=89632>
Print this page
</portal/site/ASCOv2/template.RAW/menuitem.a1c60e38cd6d5b9f01ae0094ef37a01d/;jsessionid=nrPGP0DZ9wpJZGwwD0X42pHy9YK8vJrmRblB15kXTv7GMrvnyzDj!-36294903!252569393?javax.portlet.tpst=b2e033002b246c2828a46427ef37a01d_ws_RW&javax.portlet.prp_b2e033002b246c2828a46427ef37a01d_viewID=abst_detail_rawview&javax.portlet.begCacheTok=com.vignette.cachetoken&javax.portlet.endCacheTok=com.vignette.cachetoken&index=n&confID=116&abstractID=89632>



Sub-category:
Renal Cell Cancer
</ASCOv2/Meetings/Abstracts?&vmview=abst_category_abstracts_view&confID=116&subCatID=40>


Category:
Genitourinary Cancer

Meeting:
2012 Genitourinary Cancers Symposium
</ASCOv2/Meetings/Abstracts?&vmview=abst_meeting_categories_view&confID=116>


Session Type and Session Title:
General Poster Session E: Renal Cancer

Abstract No:
439

Citation:
J Clin Oncol 30, 2012 (suppl 5; abstr 439)

Author(s):
Robert E. Hawkins, Victoria Galvis, Jonathan Shanks, Neha Dalal, Fiona
Thistlethwaite, Andrea Spencer-Shaw; Christie Cancer Research UK,
Manchester, United Kingdom; The Christie, Manchester, United Kingdom

Abstract Disclosures
<http://www.asco.org/portal/jsp/ascov2/generateAbstractCOI.jsp?abstractId=89632>


Abstract:

*Background: * High-Dose Interleukin-2 (HD IL2) remains a good option
for treatment of metastatic renal cancer. As a first-line treatment, in
carefully selected patients, it can produce high rates of response ( OR
50%; CR 25%) (Shablak A et al., J Immunotherapy 2011, 34(1):107-122).
Its use after targeted therapies is controversial and there are reports
of increased toxicity, particularly an increased incidence of
cardiovascular toxicity (and possibly a reduced response rate (Cho DC et
al., J Immunotherapy 2009, 32(2):181-520). However, there is potential
to use it either in patients who have failed treatment with targeted
therapy or as a consolidation therapy after successful treatment with a
targeted agent. *Methods: * Here we present the outcomes of 16 patients
treated with first-line immunotherapy with HD-IL2 after targeted
therapy: of these 8 had been treated after failure of 1-3 lines of
targeted therapy and 8 have been treated as consolidation after initial
response to sunitinib. The histological characteristics of the tumours
all fitted into the “favourable” group as defined previously by us and
all had high levels of expression of CAIX (> 80%). All had ECOG PS 0/1,
a satisfactory baseline stress echo, an interval of at least 8 weeks
from last dose of targeted agent to start of HD-IL2 and at most 2 organs
of disease. *Results: * Toxicity is indistinguishable from that of
patients without prior treatment and no patient needed inotropic support
or admission to intensive care. The number of doses given per cycle was
also similar to that in unpretreated patients. Overall the response
rates are excellent – with 9/13 evaluable patients having RECIST defined
response and 6/13 having a complete remission. To date none of the
patients in complete remission have realpsed but follow up is relatively
short with the longest being 24 months. The responses have been
particularly striking following treatment with mTor inhibitors.
*Conclusions: * Overall, HD IL2 can be given safely in carefully
selected patients after targeted therapies. It appears to be effective
as a salvage therapy and potentially as a consolidation therapy. Updated
results will be presented.


  Associated Presentation(s):

     	

1. Treatment of metastatic renal cancer with high-dose interleukin-2
after targeted therapy.

Meeting: 2012 Genitourinary Cancers Symposium
</ASCOv2/MultiMedia/Virtual+Meeting?&vmview=vm_meeting_tracks_view&confID=116>

Presenter: Robert E. Hawkins
</ASCOv2/Meetings/Abstracts/Speaker?&spk=Robert+E.+Hawkins&index=n>
</ASCOv2/Meetings/Abstracts/Speaker?&spk=Robert+E.+Hawkins&epdAll=Y>
Session: General Poster Session E: Renal Cancer
</ASCOv2/MultiMedia/Virtual+Meeting?&vmview=vm_session_presentations_view&confID=116&sessionID=4740>
(General Poster Session)


  Other Abstracts in this Sub-Category:

     	

1. Phase II study combining personalized dendritic cell (DC)-based
therapy, AGS-003, with sunitinib in metastatic renal cell carcinoma
(mRCC).
</ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=116&abstractID=89327>

Meeting: 2012 Genitourinary Cancers Symposium
</ASCOv2/Meetings/Abstracts?&vmview=abst_meeting_categories_view&confID=116>
  Abstract No: 348   First Author: Robert A. Figlin
</ASCOv2/Meetings/Abstracts/Speaker?&spk=Robert+A.+Figlin&index=n>
</ASCOv2/Meetings/Abstracts/Speaker?&spk=Robert+A.+Figlin&epdAll=Y>
Category: Genitourinary Cancer - Renal Cell Cancer
</ASCOv2/Meetings/Abstracts?&vmview=abst_category_abstracts_view&confID=116&subCatID=40>


     	

2. Meta-analysis of randomized control trials for the incidence and risk
of treatment-related mortality in patients with cancer treated with
vascular endothelial growth factor tyrosine kinase inhibitors.
</ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=116&abstractID=88171>

Meeting: 2012 Genitourinary Cancers Symposium
</ASCOv2/Meetings/Abstracts?&vmview=abst_meeting_categories_view&confID=116>
  Abstract No: 349   First Author: Christopher J. Richards
</ASCOv2/Meetings/Abstracts/Speaker?&spk=Christopher+J.+Richards&index=n> </ASCOv2/Meetings/Abstracts/Speaker?&spk=Christopher+J.+Richards&epdAll=Y>

Category: Genitourinary Cancer - Renal Cell Cancer
</ASCOv2/Meetings/Abstracts?&vmview=abst_category_abstracts_view&confID=116&subCatID=40>


     	

3. Effect of preoperative antiangiogenic treatment and subsequent
discontinuation on angiogenesis in the primary tumor in patients with
RCC.
</ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=116&abstractID=89124>

Meeting: 2012 Genitourinary Cancers Symposium
</ASCOv2/Meetings/Abstracts?&vmview=abst_meeting_categories_view&confID=116>
  Abstract No: 350   First Author: Axel Bex
</ASCOv2/Meetings/Abstracts/Speaker?&spk=Axel+Bex&index=n>
</ASCOv2/Meetings/Abstracts/Speaker?&spk=Axel+Bex&epdAll=Y>
Category: Genitourinary Cancer - Renal Cell Cancer
</ASCOv2/Meetings/Abstracts?&vmview=abst_category_abstracts_view&confID=116&subCatID=40>


     	

More...
</ASCOv2/Meetings/Abstracts?&vmview=abst_category_abstracts_view&confID=116&subCatID=40>


  Abstracts by Robert E. Hawkins:

     	

1. Identification of pre- and post-treatment markers of efficacy in
patients with renal cancer treated with MVA-5T4 in a phase III study.
</ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=76499>

Meeting: 2011 ASCO Annual Meeting
</ASCOv2/Meetings/Abstracts?&vmview=abst_meeting_categories_view&confID=102>
  Abstract No: 2542   First Author: R. Harrop
</ASCOv2/Meetings/Abstracts/Speaker?&spk=R.+Harrop&index=n>
</ASCOv2/Meetings/Abstracts/Speaker?&spk=R.+Harrop&epdAll=Y>
Category: Developmental Therapeutics - Clinical Pharmacology and
Immunotherapy - Immunotherapy and Biologic Therapy
</ASCOv2/Meetings/Abstracts?&vmview=abst_category_abstracts_view&confID=102&subCatID=420>


     	

2. Sunitinib (SU) treatment (trx) patterns and toxicity in patients
(pts) with advanced renal cell carcinoma (RCC) in United Kingdom (UK).
</ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=102&abstractID=83803>

Meeting: 2011 ASCO Annual Meeting
</ASCOv2/Meetings/Abstracts?&vmview=abst_meeting_categories_view&confID=102>
  Abstract No: e15150   First Author: J. Wagstaff
</ASCOv2/Meetings/Abstracts/Speaker?&spk=J.+Wagstaff&index=n>
</ASCOv2/Meetings/Abstracts/Speaker?&spk=J.+Wagstaff&epdAll=Y>
Category: Genitourinary Cancer - Kidney Cancer
</ASCOv2/Meetings/Abstracts?&vmview=abst_category_abstracts_view&confID=102&subCatID=105>


     	

3. A randomized, double-blind phase III study (VEG105192) of pazopanib
(paz) versus placebo (pbo) in patients with advanced/metastatic renal
cell carcinoma (mRCC): Updated safety results.
</ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=104&abstractID=72563>

Meeting: 2011 Genitourinary Cancers Symposium
</ASCOv2/Meetings/Abstracts?&vmview=abst_meeting_categories_view&confID=104>
  Abstract No: 313   First Author: C. N. Sternberg
</ASCOv2/Meetings/Abstracts/Speaker?&spk=C.+N.+Sternberg&index=n>
</ASCOv2/Meetings/Abstracts/Speaker?&spk=C.+N.+Sternberg&epdAll=Y>
Category: Genitourinary Cancer - Renal Cell Cancer
</ASCOv2/Meetings/Abstracts?&vmview=abst_category_abstracts_view&confID=104&subCatID=40>


     	

More...
</ASCOv2/Meetings/Abstracts/Speaker?&spk=Robert+E.+Hawkins&index=n>
</ASCOv2/Meetings/Abstracts/Speaker?&spk=Robert+E.+Hawkins&epdAll=Y>


  Presentations by Robert E. Hawkins:

     	

1. Treatment of metastatic renal cancer with high-dose interleukin-2
after targeted therapy.

Meeting: 2012 Genitourinary Cancers Symposium
</ASCOv2/MultiMedia/Virtual+Meeting?&vmview=vm_meeting_tracks_view&confID=116>

Presenter: Robert E. Hawkins, PhD, FRCP
</ASCOv2/Meetings/Abstracts/Speaker?&spk=Robert+E.+Hawkins&index=n>
</ASCOv2/Meetings/Abstracts/Speaker?&spk=Robert+E.+Hawkins&epdAll=Y>
Session: General Poster Session E: Renal Cancer
</ASCOv2/MultiMedia/Virtual+Meeting?&vmview=vm_session_presentations_view&confID=116&sessionID=4740>
(General Poster Session)

     	

2. An open-label extension study to evaluate safety and efficacy of
pazopanib in patients with advanced renal cell carcinoma (RCC).

Meeting: 2009 ASCO Annual Meeting
</ASCOv2/MultiMedia/Virtual+Meeting?&vmview=vm_meeting_tracks_view&confID=65>

Presenter: Robert E Hawkins, MD, PhD
</ASCOv2/Meetings/Abstracts/Speaker?&spk=Robert+E+Hawkins&index=n>
</ASCOv2/Meetings/Abstracts/Speaker?&spk=Robert+E+Hawkins&epdAll=Y>
Session: Genitourinary Cancer
</ASCOv2/MultiMedia/Virtual+Meeting?&vmview=vm_session_presentations_view&confID=65&sessionID=3091>
(General Poster Session)

     	

3. Phase I/II trial of a PrimeBoost therapeutic vaccine in stage III/IV
metastatic melanoma.

Meeting: 2006 ASCO Annual Meeting
</ASCOv2/MultiMedia/Virtual+Meeting?&vmview=vm_meeting_tracks_view&confID=40>

Presenter: Robert E Hawkins
</ASCOv2/Meetings/Abstracts/Speaker?&spk=Robert+E+Hawkins&index=n>
</ASCOv2/Meetings/Abstracts/Speaker?&spk=Robert+E+Hawkins&epdAll=Y>
Session: Melanoma
</ASCOv2/MultiMedia/Virtual+Meeting?&vmview=vm_session_presentations_view&confID=40&sessionID=1953>
(Poster Discussion Session)

     	

More...
</ASCOv2/Meetings/Abstracts/Speaker?&spk=Robert+E.+Hawkins&index=n>
</ASCOv2/Meetings/Abstracts/Speaker?&spk=Robert+E.+Hawkins&epdAll=Y>


  /Educational Book Manuscripts by Robert E. Hawkins/:

     	

No items found.





/This online resource is supported by:/



 
Terms & Conditions </ASCOv2/About+ASCO/Terms+%26+Conditions> • Privacy
Policy </ASCOv2/About+ASCO/Privacy+Policy> • Sponsor
<http://www.conquercancerfoundation.org/foundation/Become+a+Donor/Ways+to+Give/Corporate+%2526+Non-Profit+Funding>
• Contact Us </ASCOv2/About+ASCO/Contact+Us> • Relationships with
Industry
</ASCOv2/About+ASCO/ASCO+Information/Governance+Documents/ASCO's+Policies+and+Safeguards+for+Relationships+with+Industry>
• Site Map </ASCOv2/About+ASCO/Sitemap>
2318 Mill Road, Suite 800, Alexandria, VA 22314   |   phone: (571) 483-1300
© 2005–2012 American Society of Clinical Oncology (ASCO).  All rights
reserved worldwide.
Feedback Form
<http://www.kampyle.com/feedback_form/ff-feedback-form.php?site_code=2407282&lang=en&form_id=58106>